Searching across hundreds of databases
Proteasome inhibitors have been frequently used in treating hematologic and solid tumors. They are administered individually or in combination with other regimens, to prevent severe side effects and resistance development. Because they have been shown to be efficient and are pharmaceutically available, we tested the first Food and Drug Administration-approved proteasome inhibitor bortezomib alone and in combination with another proteasome inhibitor, salinosporamid A, in pheochromocytoma cells. Pheochromocytomas/Paragangliomas (PHEOs/PGLs) are neuroendocrine tumors for which no definite cure is yet available. Therefore, drugs with a wide spectrum of mechanisms of action are being tested to identify suitable candidates for PHEO/PGL treatment. In the current study, we show that bortezomib induces PHEO cell death via the apoptotic pathway in vitro and in vivo. The combination of bortezomib with salinosporamid A exhibits additive effect on these cells and inhibits proliferation, cell migration and invasion, and angiogenesis more potently than bortezomib alone. Altogether, we suggest these proteasome inhibitors, especially bortezomib, could be potentially tested in PHEO/PGL patients who might benefit from treatment with either the inhibitors alone or in combination with other treatment options.
Pubmed ID: 28938421 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study cell signaling pathways that impact human health.
View all literature mentionsMus musculus with name Crl:NU(NCr)-Foxn1nu from IMSR.
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis polyclonal targets Ki67 antibody - Proliferation Marker
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis monoclonal targets Human Tubulin, beta
View all literature mentionsThis monoclonal targets PARP1
View all literature mentionsThis monoclonal targets Casp3
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis polyclonal targets CD31
View all literature mentionsThis polyclonal targets RPS27A
View all literature mentionsThis monoclonal targets Caspase-3 (8G10) Rabbit mAb
View all literature mentionsThis polyclonal targets Ki67 antibody - Proliferation Marker
View all literature mentionsThis monoclonal targets PARP1
View all literature mentionsThis monoclonal targets Human Tubulin, beta
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis monoclonal targets Casp3
View all literature mentionsThis polyclonal targets CD31
View all literature mentionsThis polyclonal targets RPS27A
View all literature mentionsThis monoclonal targets Caspase-3 (8G10) Rabbit mAb
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis monoclonal targets PARP1
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis monoclonal targets Casp3
View all literature mentionsThis monoclonal targets Human Tubulin, beta
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis polyclonal targets Ki67 antibody - Proliferation Marker
View all literature mentionsThis polyclonal targets CD31
View all literature mentionsThis polyclonal targets RPS27A
View all literature mentionsThis monoclonal targets Caspase-3 (8G10) Rabbit mAb
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis polyclonal targets Ki67 antibody - Proliferation Marker
View all literature mentionsThis monoclonal targets Casp3
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis monoclonal targets Human Tubulin, beta
View all literature mentionsThis monoclonal targets PARP1
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
